Inventiva S.A.

Paris Stock Exchange IVA.PA

Inventiva S.A. EPS (Diluted) for the year ending December 31, 2023: USD -2.68

Inventiva S.A. EPS (Diluted) is USD -2.68 for the year ending December 31, 2023, a -91.36% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Inventiva S.A. EPS (Diluted) for the year ending December 31, 2022 was USD -1.40, a 3.05% change year over year.
Inventiva S.A. EPS (Diluted) for the year ending December 31, 2021 was USD -1.45, a -27.26% change year over year.
Inventiva S.A. EPS (Diluted) for the year ending December 31, 2020 was USD -1.14, a 20.91% change year over year.
Inventiva S.A. EPS (Diluted) for the year ending December 31, 2019 was USD -1.44, a 23.47% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

Paris Stock Exchange: IVA.PA

Inventiva S.A.

CEO	Mr. Frederic Cren
IPO Date	Feb. 15, 2017
Location	France
Headquarters	50 rue de Dijon
Employees	123
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Composite Materials Pet Food Pharmaceuticals Plastics Vaccines

Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Key trends

Past 5 years